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Abstract
Background: Persistent high-risk (HR) human papillomavirus (HPV) infection and increased HR-HPV viral load are
associated with the development of cancer. This study investigated the effect of human immunodeficiency virus
(HIV) co-infection, HIV viral load and CD4 count on the HR-HPV viral load; and also investigated the predictors of
cervical abnormalities.
Methods: Participants were 292 HIV-negative and 258 HIV-positive women. HR-HPV viral loads in cervical cells were
determined by the real-time polymerase chain reaction.
Results: HIV-positive women had a significantly higher viral load for combined alpha-9 HPV species compared to
HIV-negative women (median 3.9 copies per cell compared to 0.63 copies per cell, P = 0.022). This was not observed
for individual HPV types. HIV-positive women with CD4 counts >350/μl had significantly lower viral loads for
alpha-7 HPV species (median 0.12 copies per cell) than HIV-positive women with CD4 ≤350/μl (median 1.52 copies
per cell, P = 0.008), but low CD4 count was not significantly associated with increased viral load for other HPV
species. High viral loads for alpha-6, alpha-7 and alpha-9 HPV species were significant predictors of abnormal
cytology in women.
Conclusion: HIV co-infection significantly increased the combined alpha-9 HPV viral load in women but not viral
loads for individual HPV types. High HR-HPV viral load was associated with cervical abnormal cytology.
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Background
Persistent cervical infection with high-risk (HR) human
papillomavirus (HPV) leads to the development of cer-
vical lesions and this is accelerated in human immuno-
deficiency virus (HIV)-positive women [1-3]. HIV co-
infected women appear to progress to cervical cancer
much earlier than HIV-negative women [4,5]. Immune
competence plays an important role in cervical disease
progression. Women with low CD4 cell counts have a
higher HPV viral load, and a greater risk of persistent
HPV infection and cervical cancer [6,7].
The increased HPV viral load and low CD4 counts
among HIV-positive women increases the probability of
developing cervical cancer [7-9]. The HPV viral load is
positively associated with the extent of cervical abnor-
malities. The HPV viral load is also positively associated
with the frequency of HPV DNA integration [10,11].
However it is not clear whether HIV has an effect on
cervical abnormalities after controlling for known asso-
ciations with HR-HPV viral load.
In the present study we detected and quantified genital
HPV types in women using the in-house real-time poly-
merase chain reaction (RT-PCR). The objectives of the
study were (i) to detect and quantify the respective HR-
HPV types in HIV-positive and HIV-negative women;
(ii) to investigate the effect of HIV co-infection on HR-
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HPV viral load; and (iii) to investigate predictors of cer-
vical abnormality.
Methods
Study population and specimen collection
Study participants were recruited through clinics, bus stops
and taxi ranks. Eligible individuals were asked to come to
Manyanani clinic (a research clinic based in Empilisweni
centre, Gugulethu, Cape Town, South Africa) with their
sexual partner between 2006 and 2009. The Research Ethics
Committee of the University of Cape Town approved all as-
pects of the investigation (reference: 258/2006) and in-
formed consent was obtained. A total of 258 HIV-positive
women and 292 HIV-negative women were enrolled for
this study. For enrolment we did not select certain partici-
pants; however, as they were coming in they were enrolled
[12]. Samples were collected and stored as described by
Mbulawa et al., [13].
Detection and quantification of HPV DNA
DNA was extracted from cervical cells using the MagNA
Pure Compact Nucleic Acid Isolation Kit (Roche diagnos-
tics, Mannheim, Germany) and automated Roche MagNA
Pure Compact machine. DNA was stored at -20°C and
shipped to University of Uppsala, Sweden for detection and
quantification of HR-HPV DNA. The real-time PCR assay
used in this study has been reported to have similar sensi-
tivity and specificity to Hybrid Capture 2 (Qiagen, Hilden,
Germany), a United States Food and Drug Administration
approved assay [14]. HR-HPV was detected and quantified
as described by Gustavsson et al., [14].
The assay used was based on four parallel real-time PCRs
from each DNA sample, one reaction to quantify the
amount of a human single-copy gene (house-keeping gene;
Homo sapiens hydroxymethylbilane synthase (HMBS);
GenBank accession no. M95623.1) and the three other re-
actions to detect and quantify HR-HPVs (HPV-16, -18, -31,
-33, -35, -39, -45, -51, -52, -56, -58, and -59). The results
are presented as individual types, except for HPV-18 and
-45, which are detected as a phylogenetically-related group,
and HPV-33, -52, and -58, which are similarly detected.
The real-time PCR assay was carried-out in a final volume
of 25 μl, containing 3 μl template DNA from cervical cells,
Taqman® Universal PCR master mix with no AmpErase®
UNG (Applied Biosystems, Inc, Foster City, CA,
USA), 3.1 μg of bovine serum albumin (Sigma,
St Louis, MO, USA), 200 nM of each primer
(Thermo Hybaid, Waltham, MA, USA) and probe
(Applied Biosystems, Inc, Foster City, CA, USA).
Primers and probes are listed in Table 1 of
Gustavsson et al., [14].
Amplification and detection steps were performed using
the 7900 HT Sequence Detection System (Applied Biosys-
tems, Inc, Foster City, CA, USA). The amplification ramp
includes an initial hold program of 10 minutes at 95°C
followed by a two-step cycle consisting of 95°C for 15 sec-
onds and 57°C for 1 minute that was repeated 40 times.
The sensitivity of the HPV assay was determined using
plasmids containing the full genome of different HPV types
according to Moberg et al. [13] and Gustavsson et al. [15]
Standard curves ranging from 102 to 105 copies were estab-
lished for each HPV type or group of HPV types to be de-
tected Gustavsson et al. [16] A highly significant linear
relationship was seen between HPV copy number and
threshold cycle (Ct) for all HPV types detected by the sys-
tem. The threshold for a positive HPV type was set at 10
copies per PCR. Similarly, a linear relationship was seen be-
tween copy number of the human HMBS gene and thresh-
old cycle, and as threshold for inclusion in the study a copy
number of 10 genomic equivalents were used. The RT-PCR
data was analysed with the applying software SDS version
2.2. HPV copies per cell were calculated by dividing HPV
copies per sample by copies of house-keeping gene HMBS.
Statistical analyses
HPV prevalence differences were evaluated using the χ2
test (EpiInfo Version 5 Statcalc). Mann-Whitney tests
were used when analysing the effect of HIV status and
CD4 counts on HR-HPV viral load. Univariate and
multivariate logistic regressions were conducted to as-
sess predictors of abnormal cytology, using STATA 11.0
(StataCorp, College Station, TX, USA). In all analyses
P-values ≤0.05 were considered significant. When
Table 1 HR-HPV viral load per cell in women according to
HIV-status
HPV type HIV-negative women HIV-positive women P-
valuen* Median (IQR) n* Median (IQR)
HPV-16 8 0.43 (0.04–1.12) 29 2.35 (0.12–17.6) 0.238
HPV-18/45 9 0.27 (0.01–4.41) 41 1.33 (0.10–18.8) 0.398
HPV-31 9 0.25 (0.04–4.88) 15 0.70 (0.01–1.47) 0.698
HPV-33/52/58 22 1.02 (0.09–17.1) 67 3.18 (0.17–105) 0.220
HPV-35 16 0.51(0.03–4.78) 24 1.14 (0.08–10.1) 0.456
HPV-39 7 0.10 (0.00–44.0) 14 0.36 (0.00–6.93) 0.709
HPV-51 3 1.15 (0.01–3.90) 19 2.17 (0.33–16.1) 0.363
HPV-56 9 0.02 (0.01–0.33) 25 0.09 (0.01–13.9) 0.339
HPV-59 8 0.09 (0.00–1.21) 14 0.01 (0.00–4.90) 0.838
α5 HPV species 3 1.15 (0.01–3.90) 19 2.17 (0.33–16.1) 0.363
α6 HPV species 9 0.02 (0.01–0.33) 25 0.09 (0.01–13.9) 0.339
α7 HPV species 24 0.15 (0.01–5.88) 58 0.65 (0.05–11.0) 0.245
α9 HPV species 47 0.63 (0.08–7.72) 100 3.90 (0.22–53.2) 0.022
Note: α5 and α6 HPV species include HPV-51 and -56 respectively; α7 HPV
species includes HPV-18, -39, -45 and -59; α9 HPV species includes HPV-16,
-31, -33, -35, -52 and -58.
P-values were calculated by Mann-Whitney test (two-tailed). Significant
P-values are in bold.
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calculating viral loads for groups of HPV types, the viral
loads of individual types were added together in people
who were infected with more than one of the types in
the group.
Results
HR-HPV prevalence in women according to HIV status
To determine if the genital sampling was adequate, the
house keeping gene Homo sapiens hydroxymethylbilane
synthase (HMBS) was quantified in each specimen.
HMBS copies were found to be <10 in 3/550 (0.5%) cer-
vical samples. The samples with <10 HMBS copies were
not included in the analysis. HIV-positive women had a
significantly higher prevalence of HR-HPV compared to
HIV-negative women (51% 131/257; 21% 61/290, re-
spectively, P < 0.0001). Among the HR-HPV positive par-
ticipants, HIV-positive women were found to have
significantly higher prevalence of multiple HR-HPV in-
fections compared to HIV-negative women (49% 65/131;
28% 17/61, respectively, P = 0.001). HIV-positive women
were found to have a higher prevalence of all the HR-
HPV types at both individual and species level compared
to HIV-negative women (Figure 1). The mean ages of
HIV-positive and HIV-negative women were 34 years
(range, 18-65 years) and 35 years (range, 18-66 years) re-
spectively. HR-HPV prevalence was significantly higher
in women aged 18-29 years (32%, 35/108) compared to
women aged 40-66 years (9%, 9/101, P = <0.0001) but
not to women aged 30-39 years (21%, 17/81, P = 0.08,
Figure 2).
HR-HPV viral load
Median HR-HPV viral loads differed substantially be-
tween types, ranging from 0.018 for type 59 (IQR: 0.005-
0.82) to 2.02 for type 51 (IQR: 0.30-14.3) and 2.73 for
types 33, 52 and 58 combined (IQR: 0.16-73.2). The me-
dian HPV viral loads per cell were consistently higher in
HIV-positive women compared to HIV-negative women
(except for HPV-59) at the individual level; however, the
differences were not statistically significant. When HPV
types were grouped according to HPV species, HIV-
positive women were found to have a significantly higher
number of copies per cell for the α9 HPV species, com-
pared to HIV-negative women (median 3.90 compared
to 0.63 copies per cell, P = 0.022) but not for α7 HPV
species (Table 1). HIV-positive women with CD4 counts
>350/μl had significantly lower α7 HPV species viral
loads (N = 26, median 0.12 copies per cell) than HIV-
positive women with CD4 ≤350/μl (N = 32, median 1.52
copies per cell, P = 0.008), but none of the median HPV
viral loads for other HPV types or species were found to
be significantly lower in HIV-positive women with CD4
counts >350/μl (results not shown). Further analysis sug-
gested that species 9 viral loads, and viral loads for types
33, 52 and 58 combined, were significantly higher in
women with CD4 counts >500 than in lower CD4 strata,
while species 7 viral load levels were highest in the 201-
350 category (Additional file 1: Table S1). The associa-
tions between HPV viral load and age was investigated
and it was found to be significant only in the case of
HPV-39; for each year of increase in age, there was a
0.079 (95% confidence interval (CI): 0.01-0.15) reduction
in the logarithm of the HPV-39 viral load.
Predictors of abnormal cervical cytology
A total of 388 (72%) had normal cervical cytology, 52
(10%) had atypical squamous cell of undetermined sig-
nificance (ASCUS), 82 (15%) had low-grade squamous
intraepithelial lesion (LSIL), and 12 (2%) had high-grade
squamous intraepithelial lesion (HSIL). Table 2 presents
Figure 1 High-risk human papillomavirus genotypes in women according to HIV status. White bars indicate HIV-negative women and black
bars indicate HIV-positive women.
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Figure 2 High-risk human papillomavirus prevalence in women according to HIV status and age. White bars indicate HIV-negative women
and black bars indicate HIV-positive women.
Table 2 The predictors of abnormal cervical cytology in women (univariate analysis)
Variable OR 95% CI P-value
Age group
<30 years 1 0.070
30–39 years 1.31 0.84–2.03
≥40 years 0.73 0.44–1.20
HIV-positive 2.35 1.59–3.48 <0.001
Living together with study partner 0.93 0.63–1.37 0.700
Per 1-year increase in relationship duration 0.92 0.84–1.01 0.065
Per 1-year increase in age at first sex 1.07 0.99–1.16 0.086
Per 10-unit increase in number of sex acts/month 1.01 0.87–1.16 0.930




Ever used a condom with current study partner 1.23 0.81–1.87 0.340
Experienced genital discharge in last 6 months 1.09 0.66–1.81 0.730
Experienced genital ulcer in last 6 months 1.50 0.7–3.20 0.310
α5 HPV infection 3.40 1.44–8.06 0.006
α6 HPV infection 5.59 2.69–11.62 <0.001
Species 7 HPV infection
None 1 <0.001
Species 7 VL = 0.6 copies per cell (median) 4.82 2.82–8.24
Per unit increase in log copies per cell 1.55 1.15–2.08
Species 9 HPV infection <0.001
None 1
Species 9 VL = 2.5 copies per cell (median) 7.23 4.58–11.40
Per unit increase in log copies per cell 1.66 1.28–2.15
Note: *Covariate data were missing for some women and the total observations therefore sum to less than 550 for certain univariate analyses. VL: viral load per
cell, α5 HPV species is HPV-51; α6 HPV species is HPV-56; α7 HPV species are HPV-18, -39, -45 and -59; α9 HPV species are HPV-16, -31, -33, -35, -52 and -58.
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factors that were associated with abnormal cervical cy-
tology (univariate analysis). HIV-positive women were at
greater risk of having abnormal cervical cytology [odds
ratio (OR), 2.35 (95% CI: 1.59-3.48)]. HIV-positive
women with CD4 counts <350/μl were not found to
have higher risk of having abnormal cervical cytology
compared to those with CD4 counts ≥350/μl [OR, 1.42
(95% CI: 0.85-2.38)]. The HIV viral load was also not
found to be significantly associated with abnormal cer-
vical cytology [OR, 1.03 (95% CI: 0.84-1.26) per unit in-
crease in log viral load].
Other predictors of abnormal cervical cytology were
found to be infection with α5, α6, α7 or α9 HPV species.
In women infected with α7 HPV species, the α7 HPV
viral load was strongly associated with abnormal cervical
cytology [OR 1.55 (95% CI: 1.15-2.08) per unit increase
in log viral load]. Similarly, in women infected with α9
HPV species, the odds of abnormal cervical cytology
were significantly associated with α9 HPV viral load [OR
1.66 (95% CI: 1.28-2.15) per unit increase in log viral
load] (Table 2). In multivariate analysis HIV status was
not a significant predictor of abnormal cytology, and
only high α6, α7 and α9 HPV species viral loads
remained as predictors of abnormal cytology (Table 3).
Discussion
In this study we investigated the HR-HPV viral load in
HIV-positive and HIV-negative women. To our knowledge
this is the first study to report individual HR-HPV type viral
loads in HIV-positive and HIV-negative women detected
by this kind of RT-PCR assay. HIV co-infection significantly
increased cervical HR-HPV prevalence in HIV-positive
women. The prevalence of HR-HPV in HIV-positive
women (73.3%) and HIV-negative women (45.5%) was
lower than that reported by Luchters et al., [17]. This differ-
ence could be due to the fact that the current study in-
cluded 12 HR-HPV types, while that of Luchters et al.
studied 15 types , 3 more HR-HPV types (HPV-53, -66 and
-68) compared to our study [17]. The high HR-HPV preva-
lence and viral load in HIV-positive women may be due to
the immune suppression caused by HIV infection, which
could also result in the reactivation of latent infection and a
high susceptibility to new HPV acquisition [6,18]. The in-
creased rate of latent HPV infection reactivation and a high
susceptibility to new HPV acquisition among HIV-positive
individuals also results in a high prevalence of multiple in-
fections [6,19].
HIV-positive women were found to have increased α9
HPV viral load compared to HIV-negative women, similar
to findings reported in other studies [2,15,17,19,20]. The
observed significantly higher viral load in HIV-positive
women when α9 HPV species were combined but not for
the individual HPV types may be explained by two factors.
Firstly, the larger numbers of α9 HPV-positive cases, when
compared to the numbers positive for individual types, im-
plies greater statistical power to detect an HIV effect. Sec-
ondly, HIV is known to increase the risk of multiple HPV
types [19], therefore an individual infected with multiple α9
types is likely to have a higher combined α9 viral load than
an individual infected with a single α9 type.
The association of the immune system with HPV viral
load is reflected in the increasing α7 HPV viral load with
decreasing CD4 count among HIV-positive women. Levi
et al. reported that women with low CD4 counts were at
increased risk of high HPV viral load and cervical abnor-
mal cytology compared to women with higher CD4
counts [6]. We did not find a consistent effect of CD4
count on HPV viral load, similar to other studies dem-
onstrating inconsistent effects of CD4 count on HPV
viral load [7,16,21]. The low numbers of participants in
the groupings for CD4 count limited the statistical
power in determining the association between CD4
count and HR-HPV viral load.
HIV infection and high HPV viral load were found to
be predictors of abnormal cytology, however; in multi-
variate analysis after controlling for HPV viral load, the
effect of HIV status on this association was not statisti-
cally significant [22-24]. Infection with HPV species α6,
α7 and α9 (and high viral loads in the case of species α7
and α9) were found to be predictors of abnormal cy-
tology in this report. High HPV viral load has previously
been reported as a predictor of HPV persistent infection
and risk of developing precancerous lesions and cancer
[25,26]. In the study of Fontaine et al. women who did
not develop cervical abnormalities during follow-up
were those with stable HPV viral load, while those who
developed cervical disease were more likely to be those
with increased HPV viral load [7].
Conclusion
Although the current study is a cross-sectional study, we
observed that HIV co-infection significantly influenced
Table 3 The predictors of abnormal cervical cytology in
women, (multivariate analysis)
Variable OR 95% CI P-value
Species 6 HPV infection 5.04 2.15-12.3 <0.001
Species 7 HPV infection
None 1 <0.001
Species 7 VL = 0.6 copies per cell (median) 3.11 1.70–5.71
Per unit increase in log copies per cell 1.67 1.18–2.36
Species 9 HPV infection <0.001
None 1
Species 9 VL = 2.5 copies per cell (median) 6.19 3.81–10.10
Per unit increase in log copies per cell 1.62 1.24–2.12
Note: VL: viral load per cell, α6 HPV species is HPV-56; α7 HPV species are
HPV-18, -39, -45 and -59; α9 HPV species are HPV-16, -31, -33, -35, -52 and -58.
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HR-HPV prevalence in women and α9 HPV viral load in
women. High HR-HPV viral loads were found to be as-
sociated with cervical abnormal cytology. Data from this
study will add to the growing HPV viral load informa-
tion in South African HIV-positive and HIV-negative
women.
Ethical approval
Ethical approval was given by the Research Ethics Commit-
tee of the University of Cape Town (reference: 258/2006)
and informed consent was obtained.
Some of the results from this manuscript were presented
at the 25th International Papillomavirus Conference and
Clinical Workshop (Malmö, Sweden).
Additional file
Additional file 1: Table S1. Differences in HPV viral load in HIV-infected
women, by CD4 count.
Abbreviations
ASCUS: Atypical squamous cell of undetermined significance; CI: Confidence
interval; HIV: Human immunodeficiency virus; HMBS: Hydroxymethylbilane
synthase; HPV: Human papillomavirus; HSIL: High-grade squamous
intraepithelial lesion; HR: High-risk; LSIL: Low-grade squamous intraepithelial
lesion; RT-PCR: Real time polymerase chain reaction.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DC, DJM and ALW were responsible for study set-up and specimen
collection. ZZAM was responsible for specimen storage. IG, UG and ZZAM
were responsible for generating HPV viral load data. The first draft was
written by ZZAM, with contributions from DJM, IG, UG, LFJ, DC, and ALW.
Statistical analysis was conducted by LFJ. All authors were actively involved
in the interpretation of the data, creation and revision of the manuscript;
and approval of the final manuscript.
Acknowledgements
We thank the Bruce Allan, Nobuntu Noveve, staff (Nozizwe Makola, Zonke
Makhonza, Monde Mtyoko, Tembisa Nkompela, Zukiswa Mazula, Mkhanyiseli
Mpalali, Khunjuzwa Khume, Pamela Magona, Sindiswa Godwana, Khayalethu
Tshangela and Thokozile Tshangela) at Empilisweni centre and the study
participants.
Funding
The present study was funded by Poliomyelitis Research Fund, Medical
Research Council, Swedish International Development Cooperation Agency,
Swedish Cancer Foundation, Cancer Association of South Africa, National
Health Laboratory Services, National Research Foundation and South African
Research Chairs Initiative of the Department of Science and Technology.
Initial recruitment of couples who participated in this study was funded by
the Bill and Melinda Gates Foundation. Participants were recruited for a
study funded by the Bill and Melinda Gates Foundation.
Author details
1Institute of Infectious Disease and Molecular Medicine, University of Cape
Town, Anzio Road, Observatory, 7925 Cape Town, South Africa. 2Centre for
Infectious Disease Epidemiology and Research, School of Public Health and
Family Medicine, University of Cape Town, Cape Town, South Africa. 3School
of Public Health and Family Medicine, Women’s Health Research Unit,
University of Cape Town, Cape Town, South Africa. 4Department of
Immunology, Genetics and Pathology, Rudbeck Laboratory, University of
Uppsala, S-751 85 Uppsala, Sweden. 5National Health Laboratory Service,
Groote Schuur Hospital, Observatory, Cape Town 7925, South Africa. 6Center
for HIV and STIs, National Institute for Communicable Disease, National
Health Laboratory Service, Groote Schuur Hospital, Observatory, Cape Town
7925, South Africa.
Received: 17 January 2013 Accepted: 22 January 2014
Published: 31 January 2014
References
1. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S,
et al: Worldwide human papillomavirus etiology of cervical
adenocarcinoma and its cofactors: implications for screening and
prevention. J Natl Cancer Inst 2006, 98:303–315.
2. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al:
Cervicovaginal human papillomavirus infection in human
immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative
women. J Natl Cancer Inst 1999, 91:226–236.
3. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L: HPV in the etiology
of human cancer. Vaccine 2006, 24:1–10.
4. Palefsky J: HPV infection and HPV-associated neoplasia in immunocom-
promised women. Int J Gynecol Obstet 2006, 94:S56–S64.
5. Lomalisa P, Smith T, Guidozzi F: Human immunodeficiency virus infection
and invasive cervical cancer in South Africa. Gynecol Oncol 2000,
77:460–463.
6. Levi JE, Kleter B, Quint WGV, Fink MCS, Canto CLM, Matsubara R, et al: High
prevalence of human papillomavirus (HPV) infections and high
frequency of multiple HPV genotypes in human immunodeficiency
virus-infected women in Brazil. J Clin Microbiol 2002, 40:3341–3345.
7. Fontaine J, Hankins C, Money D, Rachlis A, Pourreaux K, Ferenczy A, et al:
Human papillomavirus type 16 (HPV-16) viral load and persistence of
HPV-16 infection in women infected or at risk for HIV. J Clin Virol 2008,
43:307–312.
8. Delmas MC, Larsen C, van Benthem B, Hamers FF, Bergeron C, Poveda JD,
et al: Cervical squamous intraepithelial lesions in HIV-infected women:
prevalence, incidence and regression. Aids 2000, 14:1775–1784.
9. Harris TG, Burk RD, Palefsky JM, Massad LS, Bang JY, Anastos K, et al:
Incidence of cervical squamous intraepithelial lesions associated with
HIV serostatus, CD4 cell counts, and human papillomavirus test results.
JAMA-J Am Med Assoc 2005, 293:1471–1476.
10. Ho CM, Cheng WF, Chu TY, Chen CA, Chuang MH, Chang SF, et al: Human
papillomaviral load changes in low-grade squamous intraepithelial
lesions of the uterine cervix. Br J Cancer 2006, 95:1384–1389.
11. Peitsaro P, Johansson B, Syrjanen S: Integrated human papillomavirus type
16 is frequently found in cervical cancer precursors as demonstrated by
a novel quantitative real-time PCR technique. J Clin Microbiol 2002,
40:886–891.
12. Schulz KF, Grimes DA: Sample size calculations in randomised trials:
mandatory and mystical. Lancet 2005, 365:1348–1353.
13. Mbulawa ZZA, Coetzee D, Marais DJ, Kamupira M, Zwane E, Allan B, et al:
Genital human Papillomavirus prevalence and human Papillomavirus
concordance in heterosexual couples are positively associated with
human immunodeficiency virus coinfection. J Infect Dis 2009,
199:1514–1524.
14. Gustavsson I, Juko-Pecirep I, Backlund I, Wilander E, Gyllensten U: Compari-
son between the Hybrid Capture 2 and the hpVIR real-time PCR for
detection of human papillomavirus in women with ASCUS or low grade
dysplasia. J Clin Virol 2009, 45:85–89.
15. Levi G, Feldman J, Holman S, Salarieh A, Strickler HD, Alter S, et al:
Relationship between HIV viral load and Langerhans cells of the cervical
epithelium. J Obstet Gynaecol Res 2005, 31:178–184.
16. Swan DC, Tucker RA, Tortolero-Luna G, Mitchell MF, Wideroff L, Unger ER,
et al: Human papillomavirus (HPV) DNA copy number is dependent on
grade of cervical disease and HPV type. J Clin Microbiol 1999,
37:1030–1034.
17. Luchters SM, Vanden Brorck D, Chersich MF, Nel A, Delva W, Mandaliya K,
et al: Association of HIV infection with distribution and viral load of HPV
types in Kenya: a survey with 820 female sex workers. BMC Infec Dis Ref
Type: Generic 2010, 10:18.
18. Theiler RN, Farr SL, Karon JM, Paramsothy P, Viscidi R, Duerr A, et al: High-
risk human papillomavirus reactivation in human immunodeficiency
Mbulawa et al. BMC Infectious Diseases 2014, 14:51 Page 6 of 7
http://www.biomedcentral.com/1471-2334/14/51
virus-infected women risk factors for cervical viral shedding.
Obstet Gynecol 2010, 115:1150–1158.
19. Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS, et al:
Natural history and possible reactivation of human papillomavirus in
human immunodeficiency virus-positive women. J Natl Cancer Inst 2005,
97:577–586.
20. Viscidi RP, Snyder B, Cu-Uvin S, Hogan JW, Clayman B, Klein RS, et al: Human
papillomavirus capsid antibody response to natural infection and risk of
subsequent HPV infection in HIV-positive and HIV-negative women.
Cancer Epidemiol Biomarkers Prev 2005, 14:283–288.
21. Denny L, Boa R, Willimson AL, Allan B, Hardie D, Stan R, et al: Human
papillomavirus infection and cervical disease in human
immunodeficiency virus-1-infected women. Obstet Gynecol 2008,
111:1380–1387.
22. Moberg M, Gustavsson I, Wilander E, Gyllensten U: High viral loads of
human papillomavirus predict risk of invasive cervical carcinoma.
Br J Cancer 2005, 92:891–894.
23. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC: Human
papillomavirus infection in women infected with the human
immunodeficiency virus. New Engl J Med 1997, 337:1343–1349.
24. Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, et al:
High load for most high risk human papillomavirus genotypes is
associated with prevalent cervical cancer precursors but only HPV16
load predicts the development of incident disease. Int J Cancer 2007,
121:2787–2793.
25. Ho GYF, Studentsov YY, Bierman R, Burk RD: Natural history of human
papillomavirus type 16 virus-like particle antibodies in young women.
Cancer Epidemiol Biomarkers Prev 2004, 13:110–116.
26. Andersson S, Safari H, Mints M, Lewensohn-Fuchs I, Gyllensten U, Johansson
B: Type distribution, viral load and integration status of high-risk human
papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer 2005,
92:2195–2200.
doi:10.1186/1471-2334-14-51
Cite this article as: Mbulawa et al.: Increased alpha-9 human
papillomavirus species viral load in human immunodeficiency virus
positive women. BMC Infectious Diseases 2014 14:51.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mbulawa et al. BMC Infectious Diseases 2014, 14:51 Page 7 of 7
http://www.biomedcentral.com/1471-2334/14/51
